Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach
Antibiotic Reimbursement in a Model Delinked from Sales: A Benchmark-Based Worldwide Approach
复制标题
与销售脱钩的抗生素报销模型：基于基准的全球方法
DOI：
10.2139/ssrn.2755033
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Kevin Outterson
中科院分区：
文献类型：
--
作者：
J. Rex;Kevin Outterson
尽管抗生素具有拯救生命的能力，并且是所有现代医疗保健的关键推动者，但它们的有效性现在受到日益上升的耐药性的威胁。不幸的是，由于发现和开发方面的挑战以及抗生素的经济性差，抗生素管道不符合健康需求。一系列公私伙伴关系正在解决发现和开发问题;然而，纠正抗生素的不良经济学将需要在全球范围内彻底改革目前的商业模式。目前的讨论集中在通过奖金、里程碑付款或类似保险的模式将奖励与抗生素销售脱钩，在这种模式中，创新将获得一系列可预测规模的固定付款。用同样的报酬奖励所有的药物可能会产生不正当的激励，以生产提供最少创新的药物。因此，我们提出了一种使用分级基准奖励的支付模式，旨在鼓励开发具有最大社会价值的抗生素，同时在全球范围内适当获得抗生素，以最大限度地提高人类健康。
Despite the life-saving ability of antibiotics and their importance as a key enabler of all of modern health care, their effectiveness is now threatened by a rising tide of resistance. Unfortunately, the antibiotic pipeline does not match health needs because of challenges in discovery and development, as well as the poor economics of antibiotics. Discovery and development are being addressed by a range of public-private partnerships; however, correcting the poor economics of antibiotics will need an overhaul of the present business model on a worldwide scale. Discussions are now converging on delinking reward from antibiotic sales through prizes, milestone payments, or insurance-like models in which innovation is rewarded with a fixed series of payments of a predictable size. Rewarding all drugs with the same payments could create perverse incentives to produce drugs that provide the least possible innovation. Thus, we propose a payment model using a graded array of benchmarked rewards designed to encourage the development of antibiotics with the greatest societal value, together with appropriate worldwide access to antibiotics to maximise human health.
影响因子：
11.8
作者：
Boucher, Helen W.;Talbot, George H.;Gilbert, David
通讯作者：
Gilbert, David